Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin + Cyclophosphamide followed by Paclitaxel vs 5-FU + Doxorubicin + Cyclophosphamide in locally advanced breast cancer
TCTR20170711001Phase 4Recruiting
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Jul 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in breast cancer comparing Doxorubicin + Cyclophosphamide followed by Paclitaxel with Fluorouracil + Doxorubicin + Cyclophosphamide (FAC) (2 arms). Started Jul 2017; status: recruiting.
02
Drugs
doxorubicincyclophosphamidepaclitaxelfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on TCTR20170711001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20170711001.